Pyxis Oncology : to Acquire Apexigen - Form 8-K : vimarsana.

Pyxis Oncology to Acquire Apexigen


Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate development


Commercially and clinically validated APXiMAB... | May 24, 2023

Related Keywords

Boston , Massachusetts , United States , American , Laras Sullivan , William Duke , Xiaodong Yang , Wilson Sonsini Goodrich Rosati , Jaym Feingold , Novarti Beovu , Pamela Connealy , Jan Pinkas , Apexigen Inc , Novartis , Pyxis Oncology Inc , American Society Of Clinical Oncology , Sidley Austin , Ladenburg Thalmann Co , Flexible Antibody Conjugation Technology , Linkedin , Nasdaq , Exchange Commission , Twitter , Pfizer , Pyxis Oncology , Acquire Apexigen , Antibody Drug Conjugate , Chief Executive Officer , Clinical Oncology , Chief Medical Officer , Oncology Conference Call , Webcast Registration , Closing Operations , Chief Financial Officer , Chief Operating Officer , Chief Scientific , Legal Advisors , Ladenburg Thalmann , Wilson Sonsini Goodrich , Mutation Lineage Guided , Private Securities Litigation Reform Act , Annual Report , Quarterly Report , Additional Information Will Be Filed , Registration Statement , Proxy Statement , Investor Relations , Nc Stock Exchange , News , Information , Press Release , Pyxis , Ncology , O , Cquire , Ositioned , It , Forefront , F , Conjugate , Commercially , End , Linically , Alidated Pyxs Us7473241013 ,